Government Tour of Teva Canada’s Stouffville Manufacturing Facility Showcases Pharmaceutical Capabilities and Underscores Economic Value to Canada
Municipal government officials from The Regional Municipality of York, Chairman and CEO, Wayne Emmerson, Chief of Staff, Lina Bigioni and Director of Economic Strategy, Jonathan Wheatle, and from the Town of Whitchurch-Stouffville, Mayor Iain Lovatt, recently toured Teva Canada Limited’s (Teva Canada) solid dose pharmaceutical manufacturing facility in Whitchurch-Stouffville, Ontario.
"The Teva Canada team was honoured to host our esteemed guests at the Stouffville facility, a Centre of Excellence within Teva Pharmaceuticals’ global supply chain,” said Michael Sine, General Manager, Teva Canada. “We were proud to highlight our contribution to the Canadian economy as well as this manufacturing facility’s capabilities."
A Centre of Pharmaceutical Excellence - The Stouffville manufacturing facility, one of North America’s largest, produces generic medicines in tablet and capsule dosage forms spanning a wide range of therapies including pain management, cardiovascular diseases, and mental health. The facility provides end-to-end manufacturing of medicines, from dispensing the raw materials to the production of the finished dosage format.
“Today’s tour reinforced our pride in having Teva Canada as part of our community for over 30 years,” said Iain Lovatt, Mayor, Town of Whitchurch-Stouffville. “The tour highlighted the complexities of end-to-end pharmaceutical manufacturing, including the strict regulatory requirements and quality standards that must be met, and the increasing importance of a local, Canadian medicine supply chain. We look forward to continuing to work with Teva Canada in Whitchurch-Stouffville.”
Economic Contributions in Canada - In 2022, to the benefit of the Whitchurch-Stouffville community, Ontarians, and Canadians, Teva Canada’s ‘s economic activity supported approximately 2,477 jobs, generated $101 million in labour income to the economy, and contributed $188 million to economic output. Additionally, each day more than 160,000 prescriptions are filled in Canada with a Teva medicine, saving the healthcare system close to $1.7 billion in 2022 alone.
“The COVID-19 pandemic stressed the importance of domestic pharmaceutical manufacturing and the safety and security it can offer,” said Wayne Emmerson, Chairman and CEO, The Regional Municipality of York. “Today’s tour of Teva’s Stouffville pharmaceutical manufacturing facility, one of the largest in North America, emphasizes the key role Teva plays in providing quality, made-in-Canada medicines for all Canadians.”